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Abstract
 
MHC class II (MHCII) molecules play a pivotal role in the induction and regulation of immune
responses. The transcriptional coactivator class II transactivator (CIITA) controls MHCII ex-
pression. The CIITA gene is regulated by three independent promoters (pI, pIII, pIV). We have
 
generated pIV knockout mice. These mice exhibit selective abrogation of interferon (IFN)-
 

 
–
induced MHCII expression on a wide variety of non-bone marrow–derived cells, including en-
dothelia, epithelia, astrocytes, and fibroblasts. Constitutive MHCII expression on cortical thy-
 
mic epithelial cells, and thus positive selection of CD4
 

 
 T cells, is also abolished. In contrast,
constitutive and inducible MHCII expression is unaffected on professional antigen-presenting
cells, including B cells, dendritic cells, and IFN-
 

 
–activated cells of the macrophage lineage.
 
pIV
 

 
/
 

 
 mice have thus allowed precise definition of CIITA pIV usage in vivo. Moreover, they
represent a unique animal model for studying the significance and contribution of MHCII-medi-
ated antigen presentation by nonprofessional antigen-presenting cells in health and disease.
 
Key words: knockout • promoter region • antigen-presenting cells • gene expression regulation • 
thymic selection
 
Introduction
 
MHC class II (MHCII)
 
*
 
 molecules play a pivotal role in
the induction and regulation of the immune response.
They are specialized for the presentation of peptides to the
TCRs of CD4
 

 
 T cells. The engagement of MHCII–pep-
tide complexes by the TCRs of CD4
 

 
 T cells is a pivotal
interaction in the adaptive immune system because it regu-
lates the development, activation, and survival of CD4
 

 
 T
cells (1, 2). During the course of these processes, the recog-
nition of MHCII–peptide complexes can have several al-
ternative consequences for the CD4
 

 
 T cells; it can trigger
activation and proliferation, induce a state of anergy, or
 
promote apoptosis. The precise outcome is determined
by a variety of parameters, including the nature of the
MHCII-positive cell and the density of the MHCII–pep-
tide complexes displayed at its surface (2). Accordingly, the
expression of MHCII molecules is tightly regulated in a
cell-specific and quantitative fashion.
Basal or constitutive MHCII expression is the hallmark
of three distinct types of bone marrow–derived cells,
namely dendritic cells (DCs), B cells, and cells of the
monocyte/macrophage lineage. These cells are collectively
referred to as professional APCs. MHCII molecules are also
expressed on cortical thymic epithelial cells (cTECs),
where they mediate positive selection of CD4
 

 
 thymocytes
(2). The majority of other cell types do not express basal
levels of MHCII molecules but can generally be induced to
express them in response to a number of stimuli, of which
IFN-
 
 
 
is by far the most potent and well known (for re-
view see references 3–5). IFN-
 

 
–induced MHCII expres-
sion has been described for a diverse set of non-bone mar-
row–derived cells in vitro and in vivo, including dermal
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fibroblasts, epithelial and endothelial cells in various organs,
astrocytes, hepatocytes, and myocytes (3–5).
While the crucial functions of MHCII molecules on
professional APCs and cTECs have been firmly established,
the importance of IFN-
 

 
–induced MHCII expression on
non-bone marrow–derived cells is far from clear. Although
numerous studies have confirmed that such nonprofessional
APCs are capable of mediating MHCII-restricted antigen
presentation in vitro, it remains unclear whether and how
this ability actually participates in immune responses in
vivo. This is an important question, because the induction
of MHCII expression on non-bone marrow–derived cells
is a widespread phenomenon that is intimately associated
with many normal and pathological immune responses (for
review see references 6–12). During the course of bacterial
or viral infections, the induction of MHCII on macro-
phages and DCs helps to induce efficient immune responses
directed against the pathogen. In addition, MHCII expres-
sion is upregulated in epithelia and endothelia, but the role
of this is much less well understood. Ectopic expression of
MHCII molecules on non-bone marrow–derived cells has
also been described in the parenchyma of various organs in
autoimmune diseases, such as autoimmune thyroiditis, multi-
ple sclerosis, rheumatoid arthritis, inflammatory bowel dis-
ease, lupus nephritis, vitiligo, Sjögren’s syndrome, and pri-
mary biliary cirrhosis. In mice and rats, systemic inflammatory
stimuli such as the intravenous injection of IFN-
 

 
 results in
a dramatic increase of MHCII throughout the body, in-
cluding not only bone marrow–derived cells but also, for
example, epithelial cells in the intestinal tract and kidney.
MHCII expression has been observed on tumor cells from
several neoplastic tissues. Finally, in organ transplantation,
the expression of MHCII molecules on endothelial and ep-
ithelial cells in the transplant and in the host tissues is a hall-
mark of organ rejection.
In the majority of the above-mentioned situations, it has
proved difficult to define the precise role of MHCII ex-
pression on nonprofessional APCs. This has been ham-
pered by the lack of simple animal models in which
MHCII expression on nonprofessional APCs can be un-
coupled in vivo from that on professional bone marrow–
derived APCs. Until now, such experiments relied essen-
tially on the use of bone marrow transfer experiments in
mice. However, elucidation of the molecular mechanisms
controlling the transcription of MHCII genes has opened
up new avenues for the manipulation of MHCII expression
in vivo.
The class II transactivator (CIITA) (13) is a non–DNA-
binding transcriptional coactivator that functions as a highly
specific and essential transactivator of MHCII genes (3, 5,
14). It was first identified by virtue of the fact that it is de-
fective in one form of the bare lymphocyte syndrome
(BLS), a primary immunodeficiency disease resulting from
a complete loss of constitutive and inducible MHCII ex-
pression in all cell types (5, 15–17). The expression pattern
of the gene encoding CIITA (called 
 
Mhc2ta
 
 in the mouse)
is the primary determinant dictating the cell type specificity
and induction of MHCII expression (3, 5, 14). A complex
regulatory region containing at least three independent
promoters (pI, pIII, and pIV) regulates expression of the
 
Mhc2ta
 
 gene (Fig. 1) (18). In vitro studies with established
cell lines and a limited number of primary cell types have
indicated that pI and pIII drive expression in bone mar-
row–derived APCs such as DCs and B cells, while pIV is
activated by IFN-
 

 
 in other cell types (18–22). No studies
have addressed the question of which promoter directs CIITA
expression in cTECs.
To dissect the regulatory mechanisms controlling 
 
Mhc2ta
 
expression in vivo, we have generated knockout mice in
which pIV has been deleted. To our knowledge, this is the
first description of a selective deletion of one promoter
within a gene controlled by multiple promoters. Analysis of
 
Mhc2ta
 
 and MHCII expression in pIV
 

 
/
 

 
 mice demon-
strates that the specificity of pIV is remarkably tight. Dele-
tion of pIV selectively abrogates IFN-
 

 
–induced MHCII
expression in non-bone marrow–derived cells and consti-
tutive MHCII expression in cTECs. In contrast, MHCII
expression is unaffected in bone marrow–derived APCs,
including DCs, B cells, and IFN-
 

 
–activated cells of the
macrophage lineage. These mice provide a unique and
powerful tool to evaluate the significance and contribution
of MHCII-mediated antigen presentation by nonprofes-
Figure 1. Cell-specific and inducible MHCII expression is controlled
by alternative usage of three promoters (pI, pIII, and pIV) of the Mhc2ta
gene. pI and pIII are primarily active in DCs and B cells, respectively,
while pIV is activated by IFN-. Usage of these promoters leads to the
transcription (arrows) and splicing of alternative first exons (open boxes)
to a shared second exon (shaded boxes). Incorporation of exons I and III
leads to the synthesis of type I and type III CIITA mRNA encoding
CIITA proteins having specific NH2-terminal extensions of 94 and 17
amino acids, respectively. In contrast, translation of type IV CIITA is
initiated at the AUG found in the shared second exon. The three differ-
ent forms of CIITA mRNA can be distinguished in RNase protection as-
say (rpa) with the indicated probes. CIITA activates transcription of
MHCII genes by associating with proteins (RFX, X2BP, and NF-Y) that
bind to MHCII promoters. ut, 5 untranslated region.
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sional APCs during the course of normal and pathological
immune responses in vivo.
 
Materials and Methods
 
Generation of pIV
 

 
 Mice.
 
Mapping and sequencing of the 5
 

 
region of the 
 
Mhc2ta
 
 gene was reported previously (18). The tar-
geting construct (see Fig. 2) was prepared in pBluescript (Strat-
agene) by standard PCR and recombinant DNA technology. It
contains, in order: (i) a unique SfiI site to linearize the construct,
(ii) a 5-kb fragment extending from the middle of the intron be-
tween exons I and III to the end of the intron between exons III
and IV, (iii) an isolated loxP sequence, (iv) a 0.5-kb fragment
containing pIV and its associated exon, (v) a loxP–flanked neo-
mycin resistance gene (
 
neo
 
), and (vi) a 9-kb fragment situated in
the intron downstream of exon IV. HindIII and BamHI sites
were introduced to facilitate Southern blot analysis. The linear-
ized targeting vector was transfected into E14.1 (129Sv) embry-
onic stem (ES) cells by electroporation, and G418-resistant clones
were selected as described (23). Homologous recombinants were
screened by PCR using a primer (5
 

 
-AGATTCAGTATGTTA-
CACAAAGTAC-3
 

 
) situated upstream of the 5
 

 
 end of the tar-
geting construct, and an internal primer (5
 

 
-TATGCTATAC-
GAAGTTATAAGC-3
 

 
) lying at the 5
 

 
 loxP site. Positive clones
were confirmed by Southern blotting using HindIII and BamHI
digests in combination with a 3
 

 
 external probe and an internal
probe (see Fig. 2). Two lines of mice carrying the pIV deletion
were obtained as follows. (i) Several independent ES cell clones
were injected into C57Bl/6 blastocysts. Chimeric mice were
then crossed to a “deleter” strain expressing 
 
cre 
 
(24). Germline
transmission was scored by coat color, and the deletion of pIV
was confirmed by Southern blot. (ii) The ES cells were trans-
fected with a 
 
cre 
 
expression vector (pOG231, originally obtained
from S. O’Gorman (The Salk Institute, La Jolla, CA; reference
25), and subclones carrying the pIV deletion were then injected
into C57Bl/6 blastocysts to obtain chimeric mice and germline
transmission of the deleted locus. Blastocyst injections were per-
formed at RCC (Itingen, Switzerland). Mice from the two inde-
pendent lines were genotyped by PCR to distinguish between
the wild-type (primers f1
 

 
r1) and deleted (primers f2
 

 
r2) al-
leles: f1, 5
 

 
-CCTAGGAGCCACGGAGCTG-3
 

 
; r1, 5
 

 
-TCCA-
GAGTCAGAGGTGGTC-3
 

 
; f2, 5
 

 
-CAGACTATCCTGAAA-
TGCC-3
 

 
; r2, 5
 

 
-CGAGATCTAGATATCGATAAGCTTG-3
 

 
.
All experiments were performed with CIITA pIV
 

 
 and pIV
 

 
littermates on a mixed Sv129–C57Bl/6 background. Animals
were housed either under specific pathogen–free conditions at
RCC or under standard conditions in a conventional mouse facil-
ity. The mice remain healthy in the conventional facility.
 
Four-Color Cytofluorimetric Analysis.
 
Ice-cooled single-cell sus-
pensions were pretreated with Fc-block (anti-CD16/CD32;
PharMingen) and then incubated with specific antibodies
(PharMingen) directed against CD4 (RM4–5), CD8 (53–6.7),
H-2K
 
b
 
 (AF6–88.5), I-A
 
b
 
 (AF6–120.1), CD11b (Mac1, M1/70),
CD11c (N418, HL3), or B220 (CD45R, RA3–6B2). 10
 
4
 
 (pri-
mary cultures) to 10
 
5
 
 (suspensions from fresh organs) cells were
analyzed on a FACSCalibur™ (Becton Dickinson).
 
Cell Preparation and Culture.
 
E14.1 ES cells from 129Sv mice
were maintained as described (23). Mouse embryonic fibroblasts
(MEFs) were isolated from 12.5-d-old fetuses. After the heads,
livers, and internal organs were discarded, the remaining fetal tis-
sues were minced, cells were resuspended in 0.05% trypsin and
flushed through a 20-gauge needle, and DMEM was added to in-
 
activate the trypsin. MEFs were stimulated for 24 h with 250 U/ml
of recombinant mouse IFN-
 
 
 
(Life Technologies). To isolate
splenic and thymic DCs, the organs were digested with collage-
nase D (Boehringer Mannheim) before preparation of single-cell
suspensions as described (26). Low-density cell fractions enriched
in DCs (
 

 
10%) were then recovered by centrifugation over an
OptiPrep™ (Nycomed) density gradient (27). Myeloid and lym-
phoid DC subsets were distinguished on the basis of CD8 stain-
ing. DCs were generated from bone marrow precursors as de-
scribed (28). Briefly, bone marrow cells were cultured for 12 d in
RPMI containing 20 ng/ml murine GM-CSF (Peprotech) to
drive DC differentiation. 250 U/ml of IFN-
 

 
 was added for the
last 36 h, or maturation was induced with 10 
 

 
g/ml LPS (Sigma-
Aldrich) for 36 h. DCs were identified by sorting for CD11c and
excluding B220 cells. Peritoneal macrophages were harvested 4–6 d
after intraperitoneal injection of 1 ml of 3% thioglycollate and
were cultured for 72 h in DMEM in the presence or absence of
250 U/ml recombinant murine IFN-
 

 
 (Life Technologies). Pri-
mary brain cells were obtained from postnatal day 1 newborn
mice. Brains were isolated, meninges were dissected out, the tissue
was crushed between two frosted glass slides, and the single-cell
suspension was cultured in DMEM/F12 (1:1; Life Technologies).
250 U/ml of recombinant mouse IFN-
 

 
 (Life Technologies) was
added during the last 5 d of culture. After 12 d of culture, astro-
cytes and microglia were identified as CD11b
 

 
 and CD11b
 

 
cells, respectively. Culture media were supplemented with 10%
FCS, 
 
l
 
-glutamine, 
 

 
-mercaptoethanol, sodium pyruvate, and an-
tibiotics. Single-cell suspensions from peripheral lymph nodes
were prepared by crushing the tissue between two frosted glass
slides. B cells were identified as B220
 

 
 cells.
 
Injection of Mice with IFN-
 

 
.
 
Newborn mice were genotyped
by PCR on tail DNA. pIV
 

 
 and pIV
 

 
 littermates were in-
jected intraperitoneally at postnatal day 3 and 4 with 100,000 U
of recombinant mouse IFN-
 

 
 (Life Technologies). The injected
mice and age matched noninjected controls were snap frozen in
OCT at postnatal day 5.
 
Immunohistochemistry.
 
8-
 

 
m sections from frozen adult or-
gans and whole newborn mice were air dried, fixed in ice-cold
acetone, blocked in PBS containing 0.6% H
 
2
 
O
 
2
 
, 5% goat serum,
and 0.1% NaN
 
3
 
, and stained with digoxygenin-conjugated anti-
body directed against MHCII (M5/114; reference 29) and F4/80
(MCA497F; Serotec). Staining was revealed using antidigoxyge-
nin peroxidase and 3-amino-9-ethyl carbazole (Sigma-Aldrich)
to give a red precipitate. Sections were counterstained with meth-
ylene blue.
 
RNase Protection Analysis.
 
RNase protection assays were per-
formed as described with 5–10 
 

 
g of RNA per sample (13).
Probes specific for the different types of CIITA mRNA (Fig. 1)
have been described (18, 30). Quantification was performed by
PhosphorImager analysis of the gels.
 
Antigen, Immunizations, and ELISA Techniques.
 
NP (4-hydroxy-
3-nitrophenyl acetyl; Cambridge Research Biochemicals) was
conjugated to CGG (chicken gamma globulin; Sigma-Aldrich)
and precipitated in alum (Sigma-Aldrich) as described elsewhere
(31). Groups of adult (10–14 wk old) CIITA
 

 
(32), I-A
 
	
 

 
(33), pIV
 

 
, and control wild-type mice were injected in the
base of the tail with 25 
 

 
g of alum-precipitated NP-CGG. Plastic
plates with 96 flat-bottomed wells were coated overnight at 4
 


 
C
with 5 
 

 
g/ml of NP4–BSA to allow for the selective detection of
high-affinity, NP-specific IgG antibodies in the tested sera. Plates
were washed with PBS, 0.01% Tween-20 and then blocked with
1% BSA. After washing, dilutions of the test sera were added and
incubated overnight at 4
 


 
C. Bound antibody was detected using
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biotinylated anti–mouse IgG (Amersham Pharmacia Biotech), fol-
lowed by streptavidin-conjugated alkaline phosphatase (Roche Di-
agnostics). Plates were developed with 
 
p
 
-nitrophenyl-phosphate
(Sigma-Aldrich), and absorbance was read at 405 nm.
 
Results
 
Generation of CIITA Promoter IV Knockout Mice.
 
 To gen-
erate CIITA pIV knockout mice, we used a gene targeting
strategy relying on the 
 
cre
 
/loxP recombination system (34,
35). Briefly, we generated a targeting construct designed to
insert an isolated loxP site upstream of pIV and a loxP-
flanked 
 
neo
 
 gene in the intron situated downstream of exon
IV (Fig. 2 A). ES cell clones in which these mutations were
integrated by homologous recombination were isolated by
a PCR strategy (see Materials and Methods), and the pres-
ence of the mutated locus was confirmed by Southern blot
experiments (Fig. 2 A). Mice carrying an 800-bp deletion
removing pIV and the adjacent exon were then generated
in parallel by two independent strategies. In the first strat-
egy, the ES cells were used to generate mice carrying the
targeted locus, and deletion of pIV, exon IV, and the 
 
neo
 
gene was then achieved in vivo by crossing them with de-
leter mice expressing 
 
cre
 
 recombinase (24). Southern blot-
ting and PCR approaches were used to follow transmission
of the wild-type, targeted, and deleted loci (Fig. 2, B and
C). In the second strategy, the ES cells were transfected
with a cre expression vector to generate the deletion in
vitro. ES cells carrying the deleted locus were then used to
generate mice. These two approaches led to the production
of two independent lines of mice carrying exactly the same
deletion of pIV and exon IV. All experimental results were
identical in the two lines. The deleted allele is transmitted
at a normal Mendelian frequency. Mice homozygous for
the deleted allele are healthy and breed well in a conven-
tional mouse facility.
To confirm that the deletion eliminates pIV-driven CIITA
mRNA expression, we performed RNase protection assays
with MEFs that had or had not been induced with IFN-
 

 
(Fig. 2 D). A probe (Fig. 1) permitting CIITA type IV
mRNA to be distinguished from transcripts derived from
the other two promoters was used. No CIITA mRNA is
Figure 2. Generation of Mhc2ta pIV/ mice. (A) The regulatory region
of the wild type Mhc2ta locus, the targeting construct, and the targeted locus
are depicted. Exons I, III, and IV are represented as open boxes, loxP sites
(P) are shown as filled triangles, and the neo gene is indicated by an open ar-
row. HindIII sites (H) used for Southern blotting are indicated. A represen-
tative blot for a positive ES cell clone is shown below: the 3 external probe
(shown below the wild-type locus) hybridizes to a 10-kb fragment in the
wild-type locus and to a 9-kb fragment in the targeted locus. (B) Cre-medi-
ated deletion of the targeted locus. The wild-type, targeted, and deleted loci
are depicted as in A. Arrows labeled f1, r1, f2, and r2 represent PCR prim-
ers used for genotyping of mice (see C). BamHI sites (B) used for Southern
blotting are indicated. A representative blot for heterozygous mice is shown
below: the internal probe (shown below the wild-type locus) hybridizes to a
3.4-kb fragment in the wild-type locus, to a 2.6-kb fragment in the targeted
locus, and to a 1-kb fragment in the deleted locus. DNA digested with
StyI was used as a molecular mass marker. (C) Genotyping of mice was done by PCR using the primer pair f1r1 to amplify a 500-bp fragment specific
for the wild-type locus and the primer pair f2r2 to amplify a 700-bp fragment diagnostic for the deleted locus. A representative experiment is shown for
the offspring derived from a cross between two heterozygous pIV/ mice. (D) Type IV CIITA mRNA is not induced in pIV/ mice. MEF isolated
from heterozygous (/) and homozygous (/) mice were cultivated in the absence (lanes 1 and 3) or presence (lanes 2 and 4) of IFN-. The pres-
ence of type IV CIITA mRNA was assayed by RNase protection using the type IV specific probe (Fig. 1). A GAPDH probe was used as internal control.
(E) Expression of types I and III CIITA mRNA is not affected by the deletion of pIV. Bone marrow–derived DCs generated from control littermates
(/) and homozygous mutants (/) were analyzed by RNase protection using the type I–specific probe (top). Total spleen RNA from pIV/ and
pIV/ animals was analyzed using the type III–specific probe (bottom). A TATA box binding protein (TBP) probe was used as internal control.
397 Waldburger et al.
detected in the absence of IFN-. In heterozygous pIV
MEFs, CIITA type IV mRNA is induced by treatment
with IFN-. This induction is abolished in the homozy-
gous pIV MEFs. CIITA mRNA derived from pI and
pIII is not detected in IFN-–treated MEFs from either
pIV or pIV mice.
To determine whether the elimination of pIV affects ex-
pression of the remaining two promoters, we performed
RNase protection assays with probes (Fig. 1) specific for
types I and III CIITA mRNA. RNA prepared from cul-
tures of bone marrow–derived DCs was used to analyze
transcripts derived from pI, the preponderant type of CIITA
mRNA in DCs (18, 30). To analyze promoter III expres-
sion, we prepared RNA from total spleen. The majority of
CIITA-positive cells in the spleen are B cells that express
type III CIITA mRNA (18). The results show that the ex-
pression levels of types I and III CIITA mRNA in DCs and
B cells are comparable in pIV and pIV mice (Fig. 2
E). The deletion of pIV does thus not have a significant ef-
fect on the expression of CIITA mRNA derived from the
other two promoters.
Selective Loss of IFN-–induced MHCII Expression on Non-
Bone Marrow–derived Cells. CIITA is a key regulator of
constitutive and inducible expression of MHCII genes.
Therefore, to assess the consequences of the pIV deletion,
we studied cell surface MHCII (I-A) expression in a variety
of primary cell types isolated from pIV mice. As pIV has
previously been implicated in IFN-–induced MHCII ex-
pression in a variety of cell types in vitro (18–22), we first
concentrated on cells that activate MHCII expression upon
exposure to this cytokine (Fig. 3).
MEFs isolated from wild-type embryos do not express
basal levels of I-A, but this expression is activated after ex-
posure to IFN- (Fig. 3 A). In MEFs isolated from ho-
mozygous pIV embryos, IFN-–induced I-A expres-
sion is completely eliminated (Fig. 3 A). In contrast to the
effect on induction of I-A, the deletion of pIV has no re-
percussion on either the basal or induced levels of MHC
class I (MHCI) expression (Fig. 3 A). Similar results have
been obtained with dermal fibroblasts from adult mice (data
not shown). It can thus be concluded that pIV is essential
for IFN-–induced CIITA (and thus MHCII) expression
in fibroblasts. This dependence is very strict, as a twofold
reduction of I-A induction is already evident in heterozy-
gous pIV mice carrying only a single wild-type Mhc2ta
allele (Fig. 3 A). The latter finding is consistent with previ-
ous experiments demonstrating that CIITA exerts a tight
quantitative control over the level of MHCII expression in
HeLa cells (36).
Surprisingly, the deletion of pIV has no effect on IFN-
–induced I-A expression on peritoneal macrophages (Fig.
3 B). The level of I-A induced on pIV macrophages is
identical to that induced on pIV macrophages (Fig. 3
B). Moreover, no difference in induction was observed be-
tween heterozygous pIV and wild-type macrophages
(data not shown). In contrast to the situation observed for
fibroblasts, pIV is thus clearly not essential for IFN-–induced
MHCII expression in macrophages.
Figure 3. Selective loss of IFN-–induced MHCII expression on
non-bone marrow–derived cells in pIV-deficient mice. (A) MEFs from
pIV/ fetuses exhibit a selective loss of IFN-–induced MHCII expres-
sion. MEFs isolated from wild-type (/), heterozygous (/), and
homozygous (/) mice were treated with IFN- and analyzed by two-
color FACS® for the induction of MHCI and MHCII expression. (B)
The deletion of pIV does not eliminate IFN-–induced MHCII expres-
sion in macrophages. Thioglycollate-elicited peritoneal macrophages
were isolated from heterozygous (/) and homozygous (/) mice,
cultured in the absence (open profile) or presence (filled profile) of IFN-,
and then analyzed by FACS® for MHCII expression. (C) IFN-–induced
MHCII expression is lost in astrocytes but retained in microglia from pIV-
deficient mice. Brain-derived cells from pIV/ mice were cultured in the
absence (open profiles) or presence (solid profiles) of IFN-. CD11b mi-
croglial cells (R2, top right) and CD11b astrocytes (R1, center right)
were analyzed by FACS® for expression of MHCII. Activation of the as-
trocytes by IFN- was verified by examining the upregulation of MHCI
expression (bottom right).
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Given the radically different effect of the pIV deletion
on fibroblasts and peritoneal macrophages, we extended
our analysis to two additional IFN-–inducible cell types,
astrocytes and microglial cells. These two cell types are
abundant in the central nervous system (CNS). Astrocytes
are non-bone marrow–derived glial cells, while microglia
are CNS-resident macrophages. Both cell types are known
to respond to IFN- by upregulating expression of MHCII
genes (37–40). We therefore studied IFN-–induced I-A
expression on astrocytes and microglia in primary brain cell
cultures (Fig. 3 C). As observed by others, I-A expression is
induced by IFN- on both microglial cells and astrocytes
from wild-type mice (data not shown). The deletion of
pIV does not abolish IFN-–induced I-A expression on
pIV microglia. In contrast, IFN-–induced I-A expres-
sion is completely abrogated on the pIV astrocytes. As
observed for MEFs, the induction of MHCI expression is
not affected in pIV astrocytes (Fig. 3 C). Taken to-
gether, these results demonstrate that pIV is essential for
IFN-–induced expression of CIITA and MHCII in non-
bone marrow–derived cells such as fibroblasts and astro-
cytes but is dispensable in bone marrow–derived cells such
as macrophages and microglia.
CIITA Promoter Usage in IFN-–activated Macrophages.
The finding that IFN-–induced MHCII expression is not
affected in macrophages from pIV mice was surprising
because pIV has previously been shown to be activated by
IFN- in primary cells and cell lines belonging to the
monocyte/macrophage lineage (18–22). We therefore ex-
amined CIITA promoter usage in IFN-–activated perito-
neal macrophages from pIV mice and littermate controls
(Fig. 4). This analysis was done by RNase protection ex-
periments using probes specific for transcripts derived from
the three Mhc2ta promoters (Fig. 1). Under the culture
conditions used, neither the control macrophages nor
pIV macrophages express basal levels of CIITA mRNA.
In agreement with previous studies, the control macro-
phages express CIITA type IV mRNA after activation with
IFN-. However, they also express high levels of CIITA
type I mRNA and a trace amount of type III mRNA. In
pIV macrophages, IFN-–induced expression of CIITA
type IV mRNA is completely abolished as expected. On
the other hand, IFN-–induced expression of type I and
type III mRNA is retained. Quantification has indicated
that CIITA type I mRNA is the predominant form in-
duced in both the control and pIV macrophages (Fig. 4
D). This explains why cell surface MHCII expression in
IFN-–activated macrophages is identical in pIV and
control macrophages (Fig. 3 B).
pIV Is Not Required for MHCII Expression in Bone Mar-
row–derived Cells. Previous in vitro studies had suggested
that pI and pIII are active primarily in DCs and B cells, re-
spectively (18, 30, 41). The strategy used to excise pIV was
designed such that it should not interfere with the synthesis
of CIITA mRNA derived from pI and pIII. The analysis of
CIITA type I transcripts in DCs from bone marrow cul-
tures and of CIITA type III transcripts in the spleen sug-
gests that this is indeed the case (Fig. 2 E). To further con-
firm this finding, we studied the effect of the pIV deletion
on I-A expression in various B cell and DC preparations
(Fig. 5). B cells were isolated from the bone marrow,
lymph nodes, and spleen. DC preparations included thymic
DCs, bone marrow–derived DCs, bone marrow–derived
DCs treated with IFN- or induced to maturate with LPS,
and splenic DCs of the lymphoid (CD8) and myeloid
(CD8) subsets. In all cases, the levels of I-A expression in
cells from the pIV mice were identical to those observed
in cells from control littermates (Fig. 5). The function of pI
and pIII in B cells and DC is thus independent of pIV.
Further confirmation that the deletion of pIV does not
affect MHCII expression on bone marrow–derived cells was
obtained by staining tissue sections with antibodies against
I-A (Fig. 5 E and Fig. 6). Various lymphoid and nonlymphoid
tissues were examined. The overall architecture of the
spleen in pIV mice is normal, as assessed by the examina-
tion of sections stained with hematoxylin and eosin and sec-
Figure 4. IFN-–induced activation of Mhc2ta expres-
sion is mediated largely by pI. Thioglycollate-elicited peri-
toneal macrophages from control (/) or homozygous
mutant (/) mice were cultured in the absence (lanes 1
and 3) or presence (lanes 2 and 4) of IFN-. Expression of
CIITA was analyzed by RNase protection using probes
specific for type IV (A), type I (B), and type III (C)
mRNA. The band corresponding to the specific mRNA
(I, III, or IV) and the band representing mRNA derived
from the other two promoters (NonI, NonIII, and
NonIV) are indicated. A probe for GAPDH mRNA was
used as internal control. The percentages of total CIITA
mRNA corresponding to types I, III, and IV were quanti-
fied by PhosphorImager analysis of RNase protection ex-
periments similar to those shown in A–C (D).
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tions stained for distribution of the DC marker CD11c to
distinguish between the T and B cell zones (data not
shown). The pattern of I-A expression in the splenic white
pulp (B cells and DCs) and on marginal zone macrophages
of pIV mice is identical to that observed in control mice
(Fig. 5 E). Similarly, pIV and control mice exhibit very
similar I-A expression patterns in Peyer’s patches (Fig. 5 E)
and lymph nodes (data not shown). Finally, I-A expression
in the pIV mice is also normal on scattered cells in vari-
ous tissues, including the brain, lungs, liver, and intestine
(Fig. 6). These MHCII-positive cells are detected both be-
fore and after administration of IFN- (Fig. 6). Staining of
adjacent sections with cell lineage markers (B220 for B cells,
CD11c for DCs, and F4/80 for macrophages) has indicated
that these MHCII-positive cells are primarily tissue macro-
phages. Colocalization of staining for I-A and the macro-
phage marker F4/80 is shown for the brain, lung, and intes-
tine in Fig. 6. Taken together these results demonstrate that
pIV of the Mhc2ta gene is not required for MHCII expres-
sion in B cells, DCs, and macrophages.
Loss of IFN-–induced MHCII Expression on Non-Bone
Marrow–derived Cells In Vivo. Widespread induction of
MHCII expression can be obtained in vivo by the injection
of IFN- into mice and rats (42–45). We used this ap-
proach to determine whether our observation that IFN-–
induced MHCII expression is abrogated in pIV fibro-
blasts and astrocytes can be extended to other non-bone
marrow–derived cells in vivo. Newborn mice were in-
jected intraperitoneally with IFN- on postnatal days 3 and
4 and were then killed on day 5. Whole embryo cryosec-
tions were stained for I-A expression. Fig. 6 shows whole
body sections and details of representative regions of the
brain, salivary gland, lung, liver, and intestines from control
(pIV) and knockout (pIV) mice that had or had not
been injected with IFN-. After administration of IFN-,
a strong induction of I-A expression is observed in the con-
Figure 5. Deletion of Mhc2ta pIV does not affect constitutive MHCII
expression in bone marrow–derived cells and secondary lymphoid tis-
sues. (A) Cells isolated from the bone marrow, lymph nodes, and spleens
of pIV/ mice and pIV/ littermate controls were analyzed by two-
color FACS® for the expression of MHCII and the B cell marker B220.
The percentage of cells in the four quadrants is indicated for each panel.
(B) FACS® analysis of MHCII expression on ex vivo B cells isolated
from the bone marrow, lymph nodes, and spleens of pIV/ mice (solid
profiles) and control littermates (open profiles). (C) MHCII expression
on ex vivo DCs isolated from pIV/ mice (solid profiles) and control
pIV/ littermates (open profiles) was examined by four-color FACS®
analysis. Cells studied were thymic (CD11cB220) DCs and splenic
DCs of the myeloid (CD11cB220CD8) and lymphoid
(CD11cB220CD8) subsets. (D) MHCII expression was analyzed by FACS® on CD11c bone marrow–derived DCs from pIV/ mice (solid profiles)
and control littermates (open profiles). The DCs were analyzed as such, after induction with IFN-, or after treatment with LPS to induce maturation. (E)
Sections of the spleen and Peyer’s patches from adult pIV/ mice and control pIV/ littermates were stained for MHCII expression (brown color).
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Figure 6. Deletion of Mhc2ta pIV results in a selective loss of IFN-–induced MHCII expression on non-bone marrow–derived cells. Sections of
newborn mice were stained for MHCII expression (brown color). (Top) Whole body sections of newborn pIV/ mice (A and C) and control pIV/
littermates (B and D) that had been injected (C and D) or had not been injected (A and B) with IFN-. Positions of the brain (b), lungs (lu), liver (li), in-
401 Waldburger et al.
trol pIV mice on a variety of non-bone marrow–derived
cell types throughout the body. I-A expression in the con-
trol mice is, for instance, induced on meninges, epithelial
cells lining the acini and main duct of the submandibular
salivary gland, epithelial cells lining the airways in the
lower respiratory tract, epithelial cells lining the bile ducts
in the liver (data not shown), epithelial cells lining the villi
and glands in the crypts of the intestine, many vascular en-
dothelial cells, such as those of the veins in the lungs and
liver, and hepatocytes (Fig. 6, panels 1D–5D). Other cell
types include parietal and visceral peritoneum, parietal and
visceral pleura, and ependymal and plexus epithelial cells in
the brain and skin fibroblasts, mostly around hair follicles
(data not shown). In all of the cell types mentioned above,
the IFN-–induced I-A expression is eliminated in the pIV
knockout mice (Fig. 6, panels 1C–5C). These results thus
confirm that pIV is essential for IFN-–induced MHCII
expression in a wide variety of non-bone marrow–derived
cells in vivo.
I-A expression in pIV mice is retained on scattered
cells in organs such as the brain, spinal cord (data not
shown), lung, and liver (Fig. 6). The distribution and local-
ization of these cells suggests that they are tissue macro-
phages. This has been confirmed by staining serial sections
for expression of I-A and the macrophage marker F4/80
(Fig. 6, bottom panels). Therefore, as observed for micro-
glia and peritoneal macrophages in vitro (Fig. 3), the dele-
tion of pIV does not abolish MHCII expression by cells of
the macrophage lineage in vivo.
Loss of MHCII Expression on cTECs. To examine the
effect of the deletion of pIV on the expression of MHCII
in the thymus, we stained thymic sections with antibodies
directed against I-A (Fig. 7 A). In wild-type thymi, the
cortex exhibits a fine reticular pattern of I-A expression
characteristic of cTECs. The more diffuse staining seen in
the medulla is attributable to DCs, B cells, and macro-
phages. Unexpectedly, pIV thymi exhibit a selective loss
of the reticular I-A staining on cTECs (Fig. 7 A). Only a
residual patchy staining remains in the cortex. In contrast to
the cortex, the diffuse staining on bone marrow–derived
cells in the medulla is unchanged (Fig. 7 A). A very similar
pattern of MHCII expression has been described in
MHCII-deficient mice repopulated with wild-type bone
marrow cells (46).
To identify the cell type that retains residual MHCII ex-
pression in the thymic cortex of pIV mice, we stained
serial sections with cell lineage–specific antibodies. The
patchy MHCII staining in the cortex is matched by the
macrophage-specific (anti-F4/80) staining that we per-
formed on adjacent sections (Fig. 7 A). This is consistent
with the fact that macrophages from pIV mice retain
MHCII expression (Figs. 3, 4, and 6). In contrast to the ex-
pression of F4/80, cells expressing CD11c (DCs) are re-
stricted to the medulla and cortico-medullary junction (Fig.
7 A), which is in accordance with previous results obtained
on other mouse strains (47). Staining with an antikeratin
antibody is consistent with a conserved architecture of the
thymic stroma (data not shown).
To determine whether MHCII expression could be re-
stored by IFN- in pIV cTECs, we examined I-A ex-
pression in the thymi of newborn mice that had received
high doses of this cytokine. The MHCII staining pattern
observed in the thymic cortex of IFN-–injected pIV
mice is similar to that seen in noninjected pIV mice
(data not shown). Therefore, as observed for other extrahe-
matopoietic cells, pIV is essential for CIITA expression in
cTECs, and its absence cannot be compensated for by IFN-
–mediated activation of pI or pIII.
Impaired Positive Selection of CD4 T Cells and T Cell–depen-
dent Immune Responses. The selective absence of MHCII
on cTECs in pIV mice has a profound impact on posi-
tive selection of CD4 T cells. Percentages of CD4 T
cells are reduced 7–10-fold in the thymus and up to 20-
fold in peripheral lymphoid organs of pIV mice (Fig. 7
B). Similar numbers were found in older pIV mice, in-
dicating that the presence of MHCII-positive APCs in pe-
ripheral organs is not sufficient in itself to lead with time to
the accumulation of significant numbers of MHCII-restricted
CD4 T cells (data not shown).
To document the functional consequences of the im-
pairment of positive selection, we examined the ability of
the pIV mice to generate a T cell–dependent immune
response (Fig. 7 C). pIV and control mice were immu-
nized with NP-CGG, and primary antibody responses at
day 15 were measured. One-half of the pIV mice pro-
duced low levels of high-affinity IgG during the primary
response, whereas no response was detected in negative
control mice (I-A	 and CIITA mice) (Fig. 7 C, left
panel). Titration curves indicate that the IgG titers pro-
duced by the responding pIV mice are at least 20-fold
lower than the titers obtained in control littermates (Fig. 7
C, right panel). All but one of the pIV mice produced
detectable but reduced levels of high-affinity IgG after a
second antigen challenge (data not shown). Taken to-
gether, these results indicate that the residual CD4 T cells
in pIV mice can sustain a T cell–dependent immune re-
sponse, albeit with a strongly reduced efficiency.
Discussion
The realization that CIITA is a key regulatory factor for
transcription of MHCII genes has kindled a great deal of
testines (i), and salivary glands (sg) are indicated. (1A–5D) Higher magnifications of representative regions of organs from the mice shown in A–D. Brain
sections (1A–1D): m, meninges; p, parenchyma. Submandibular salivary gland sections (2A–2D): d, secretory duct. Lung sections (3A–3D): v, pulmonary
veins; b, bronchioles; rb, respiratory bronchiole; bs, bronchus. Liver sections (4A–4D): v, central vein; d, bile duct. Sections through the intestines (5A–
5D) show the visceral peritoneum, crypts, and villi. (Bottom) Adjacent sections from the brain (1C), lung (3C), and intestine (5C) of IFN-–injected
pIV/ mice were stained for expression of MHCII and a macrophage-specific marker (F4/80).
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interest in the molecular mechanisms regulating its expres-
sion (3, 5, 14). A large and complex regulatory region con-
trols expression of the Mhc2ta gene. In mice, this region
contains three independent promoters (pI, pIII, and pIV)
spread out over 12 kb of DNA (18). Until now, the speci-
ficity of these promoters has been addressed almost exclu-
sively in vitro. We therefore opted for an in vivo approach
relying on the generation of Mhc2ta promoter knockout
mice. A mouse lacking pIV of the Mhc2ta gene has been
constructed. The analysis of this mouse has demonstrated
that pIV is essential for constitutive MHCII expression in
cTECs and IFN-–induced MHCII expression in non-
bone marrow–derived cells, whereas it is dispensable for
constitutive and inducible MHCII expression in DCs, B
cells, and cells of the macrophage lineage. This selective
loss of MHCII expression on non-bone marrow–derived
cells represents a novel and unusual phenotype. It contrasts
sharply with the phenotype of mice carrying null mutations
of the Mhc2ta gene, which exhibit an almost complete loss
of both constitutive and IFN-–induced MHCII expres-
sion in all tissues and cell types (32, 48, 49).
To generate the pIV knockout mice, we used a strategy
relying on the cre/loxP recombination system (34, 35).
The choice of the cre/loxP system was motivated by two
advantages. First, it permits excision of the neo gene and its
associated regulatory elements, thereby ensuring that activ-
ity of the remaining Mhc2ta promoters (pI and pIII) and the
splicing pattern of precursor RNAs is not perturbed. Sec-
ond, the cre/loxP system permits the generation of condi-
tional knockout mice in which pIV can be excised in a
temporally or spatially restricted manner (34, 35). To
achieve this, we are in the process of generating mice in
which pIV and its associated exon are left intact but flanked
by loxP sites. In these mice, pIV-dependent MHCII ex-
pression can be abrogated at specific points in time and/or
in defined cell types by the introduction of inducible and/
or tissue-specific cre transgenes.
The Mhc2ta pIV knockout mouse exhibits a selective
loss of IFN-–induced MHCII expression on non-bone
marrow–derived cells. This is evident for a variety of cell
types exposed to IFN- in vitro or in vivo, including fi-
broblasts, astrocytes, hepatocytes, and endothelial and epi-
thelial cells in various organs (Table I). In these cell types,
IFN-–induced MHCII expression exhibits a strict depen-
dence on pIV, and the remaining two promoters cannot
compensate for its absence. This is consistent with previous
RNase protection experiments and reporter gene assays,
suggesting that pIV is the main Mhc2ta promoter that is ac-
tivated by IFN- in vitro in cells such as rodent astrocytes
(21, 22, 30), human melanoma cells (18), and mouse mela-
Figure 7. Deletion of Mhc2ta pIV results in the loss of MHCII expression on cTECs
and leads to impaired positive selection of CD4 T cells. (A) Thymic sections from
pIV/ mice and pIV/ littermate controls were stained (brown color) for expression
of MHCII, the DC marker CD11c, or the macrophage marker F4/80. Regions corre-
sponding to the cortex (c) and medulla (m) are indicated. (B) T cell populations in the
thymus, lymph nodes, and spleen of pIV/ mice and pIV/ littermate controls were
analyzed by FACS® for expression of CD8 and CD4. The percentages of single-positive CD4, single-positive CD8, and double-positive cells are indicated.
(C) The ability to generate a primary T cell–dependent antibody response was examined in pIV/ mice, in pIV/ littermates, and in negative controls
(CIITA/ and I-A	/ mice). High-affinity IgG titers produced after immunization with NP-CGG were measured at the indicated dilutions of the sera.
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noma cells (data not shown) (Table I). However, it is at
odds with experiments showing that the human pIII pro-
moter can be activated by IFN-, albeit with relatively low
efficiency, in PP2 fibroblasts, human umbilical vein endo-
thelial cells (HUVECs), and certain cell lines (Table I; ref-
erences 18, 20, and 50). This discrepancy may reflect a spe-
cies-specific difference. The sequences implicated in IFN-
induction of the human pIII promoter lie far upstream in a
region that is not conserved between the human and
mouse genes. An alternative explanation may be that re-
porter gene assays do not always reproduce faithfully the
activity of the endogenous promoters. Experiments per-
formed with the choriocarcinoma cell line Jar provide a
good illustration of this point: pIV-driven reporter gene
constructs can be activated by IFN- in Jar cells (Table I),
but hypermethylation of the endogenous promoter renders
it refractory to this induction (51).
The deletion of pIV does not affect IFN-–induced CIITA
and MHCII expression in peritoneal macrophages and mi-
croglia in vitro. Induction of MHCII expression on tissue
macrophages in the lung, CNS, intestine, liver, and thymus
is also retained. Thus, although induction of pIV activity is
indeed observed in cells of the macrophage lineage, this is
not an absolute requirement for upregulation of MHCII
expression. This was rather unexpected, because pIV was
until now believed to be the major promoter responsible
for IFN-–induced expression in macrophages (18, 21).
We show here that enhanced MHCII expression in IFN-
–activated mouse macrophages is in fact ensured mainly
by pI and to only a minor extent by pIII and pIV (Fig. 4
and Table I). This is consistent with our previous finding
that transcripts derived from pI are detected in IFN-–acti-
vated microglia (30). Surprisingly, IFN-–responsive se-
quences have not been identified in the vicinity of pI. This
raises the possibility that IFN-–activated expression of pI
is mediated by a distant, as yet unidentified enhancer re-
gion. Alternatively, it is possible that IFN- does not affect
pI directly. Instead, enhanced activity of pI could be an in-
direct consequence of macrophage activation. The answer
to this question will have to await further dissection of the
regulatory mechanisms controlling pI.
Examination of MHCII expression in the thymi of
pIV/ mice revealed an unsuspected function of pIV.
cTECs in pIV/ mice are devoid of MHCII molecules,
and positive selection of CD4 T cells is consequently im-
paired. The activation of pIV in cTECs must occur via
mechanisms that are distinct from those mediating IFN-–
induced expression in other cell types. Indeed, although
cTECs can upregulate MHCII expression in response to
IFN- in vitro (52), these cells generally express MHCII
molecules in a constitutive manner in vivo and when
maintained in culture as three-dimensional aggregates (53).
This constitutive MHCII expression by cTECs is indepen-
dent of the IFN- stimulatory pathway (54). Moreover,
mice deficient for IFN- or its receptor do not exhibit im-
paired positive selection of CD4 T cells and have normal
CD4 T cell counts in the thymus and periphery (54, 55).
The fact that CD4 T cells do not accumulate in
MHCII-positive peripheral lymphoid organs of the pIV/
mice indicates that the defect in positive selection is severe.
The extent of CD4 T cell depletion in pIV/ mice is
currently being analyzed in greater detail. Preliminary re-
sults indicate that the percentages of CD4 T cells is not
significantly higher than in I-A	/ or CIITA/ mice.
Nevertheless, inefficient T cell–dependent immune re-
sponses can be elicited in pIV/ mice, indicating that the
residual CD4 T cell compartment is competent for pro-
viding help to MHCII-positive B cells. That this was not
observed previously in the classical CIITA knockout mice
can be explained by the fact that the latter lacked MHCII-
positive APCs and B cells.
The induction of MHCII expression on non-bone mar-
row–derived cells is widespread in many normal and patho-
logical CD4 T cell–mediated immune responses, includ-
ing those called into play during the course of autoimmune,
allergic, infectious, and neoplastic diseases, as well as graft
rejection. However, the contribution of this ectopic
MHCII expression on nonprofessional APCs is not well de-
Table I. CIITA Promoter Activity in IFN-–treated Cells
Approach Cell type pI pIII pIV
I. Endothelium   
Bronchial epithelium   
Pleural epithelium   
Peritoneal epithelium   
Intestinal epithelium   
Glands, intestinal tract   
Bile duct epithelium   
Skin fibroblasts   
MEFs   
Astrocytes   
II. MEFs   
Astrocytes   
Macrophages   
Microglia  ND 
THP1 monocytes   
PP2 fibroblasts ND  
HUVECs ND  
Melanoma Me67.1, 67.8   
HeLa cells ND  
B16 murine melanoma   
Jar choriocarcinoma cells ND  
U373 glioblastoma cells ND  
2fTGH fibrosarcoma cells ND  
P19 embryonal carcinoma ND  
RAW 264.7 macrophages ND  
Approach I: Absence of MHCII on pIV cells (FACS® or histology).
Approach II: RNase protection or reporter gene assays.
404 Mice Lacking Promoter IV of the Class II Transactivator Gene
fined in many of these situations. The pIV-deficient mouse
constitutes a novel means to address this question because
the deletion of pIV results in a highly selective loss of
MHCII-mediated antigen presentation by nonprofessional
APCs. In particular, we hope that the pIV knockout mouse
will be useful for a number of mouse models of CD4 T cell–
mediated autoimmune diseases in which ectopic MHCII
expression may represent a crucial feature. The following
models represent good examples. TGF-1–deficient mice
develop a fatal systemic CD4 T cell–mediated autoim-
mune disease. In this model, MHCII expression is induced
widely on nonlymphoid cells of target tissues before the ap-
pearance of other signs of inflammation (56, 57). Similarly,
induction of MHCII expression in the CNS is a key aspect
of experimental autoimmune encephalitis, a widely ac-
cepted animal model for multiple sclerosis (58, 59). Induc-
tion of MHCII expression in the kidney has been impli-
cated in models of experimental glomerulonephritis (60).
Finally, mice expressing IFN- transgenes driven by tissue-
specific promoters suffer from various inflammatory or au-
toimmune syndromes characterized by ectopic expression
of MHCII molecules (61–65). For the pIV/ mice to be
useful in such models, it will be necessary to restore positive
selection by one of the following approaches. First, positive
selection could be restored by transplanting a wild-type
thymus. Second, the conditional cre/loxP-mediated knock-
out strategy could be used to delete pIV in adult mice after
the mature T cell repertoire has been established. Finally,
positive selection could be restored by introducing a CIITA
transgene controlled by a promoter (K14) driving expres-
sion in thymic epithelial cells.
pIV/ mice represent the first dissection by gene target-
ing techniques of a complex regulatory region consisting of
multiple promoters. The precise and highly selective effect
of the loss of pIV on MHCII expression suggests that the
regulatory region controlling the Mhc2ta gene is readily
amenable to genetic manipulations in vivo without result-
ing in unwanted disturbances. For instance, our results em-
phasize the fact that pI and pIII are functionally indepen-
dent of pIV. The different Mhc2ta promoters thus do not
appear to be subjected to a significant amount of cross-talk,
and they do not affect each other’s activity. This paves the
way for further targeting experiments designed to define
the specificity of the Mhc2ta promoters in vivo. In addition
to furthering our understanding of the molecular mecha-
nisms controlling expression of CIITA and MHCII genes,
these experiments will also generate mice exhibiting novel
patterns of compartmentalized MHCII expression. We an-
ticipate that such mice will be valuable for dissecting the
respective roles of MHCII-mediated antigen presentation
by different professional and nonprofessional APCs in nor-
mal and pathological immune responses.
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